Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

Helen Dakin, S Wordsworth , Chris Rogers, G abangma, J Raferty , Simon P Harding, Andrew J Lotery, S M Downes, Usha Chakravarthy, Barnaby Reeves

Research output: Contribution to journalArticle (Academic Journal)

45 Citations (Scopus)
Original languageEnglish
Article numbere005094
JournalBMJ Open
Volume4
DOIs
Publication statusPublished - 29 Jul 2014

Structured keywords

  • BTC (Bristol Trials Centre)
  • Centre for Surgical Research

Projects

ConDuCT-II

Blazeby, J. M.

1/04/1431/03/19

Project: Research

Profiles

No photo of Barnaby C Reeves

Professor Barnaby C Reeves

Person: Academic , Member

Cite this

Dakin, H., Wordsworth , S., Rogers, C., abangma, G., Raferty , J., Harding, S. P., Lotery, A. J., Downes, S. M., Chakravarthy, U., & Reeves, B. (2014). Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open, 4, [e005094]. https://doi.org/10.1136/bmjopen-2014-005094